Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07139106 · ClinicalTrials.gov registry record · Phase 4
Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Not yet
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT07139106 is a Phase 4 study that has not yet begun recruiting, run by New York State Psychiatric Institute. The registered enrollment target is 12 participants.
The verdict
NCT07139106, a Phase 4 study, has not yet begun recruiting, sponsored by New York State Psychiatric Institute.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study explores how stress, suicidal thoughts, and ketamine's effects are connected in people with major depressive disorder. Stress increases the risk for suicidal thoughts, but the biological basis is unclear. Ketamine may help reduce suicidal thoughts by affecting stress-linked brain systems. This study will use smartphone tracking to monitor real-time responses to stress and positron emission tomography (PET) brain scans to study how ketamine affects brain pathways related to stress and suicidal thoughts in depressed individuals.
Interventions
- DRUG Ketamine hydrochloride infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2028-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07139106
The ClinicalTrials.gov registry entry for NCT07139106 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine hydrochloride infusion is the first listed.
NCT07139106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07139106 about?
NCT07139106 is a clinical study titled "Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts". This study explores how stress, suicidal thoughts, and ketamine's effects are connected in people with major depressive disorder. Stress increases the risk for suicidal thoughts, but the biological basis is unclear. Ketamine may help reduce suicidal thoughts by affecting stress-linked brain systems....
What is the current status of trial NCT07139106?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2026-05-01. Estimated completion is 2028-05-01.
What interventions are being tested in trial NCT07139106?
The interventions under investigation include: Ketamine hydrochloride infusion (DRUG).
Who is sponsoring clinical trial NCT07139106?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.